会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • 5-substituted 3-aninoalkyl indoles
    • 5-取代的3-苯基烷基吲哚
    • US4870096A
    • 1989-09-26
    • US940652
    • 1986-12-11
    • Alexander W. OxfordIan H. CoatesDavid E. BaysColin F. Webb
    • Alexander W. OxfordIan H. CoatesDavid E. BaysColin F. Webb
    • A61K31/40A61K31/403A61K31/404A61P9/00A61P25/04C07D209/16
    • C07D209/16
    • Indoles are disclosed of formula (I): ##STR1## wherein R.sub.1 represents R.sub.5 R.sub.6 NCOCH.sub.2 --, R.sub.5 CONH(CH.sub.2).sub.p --,R.sub.5 R.sub.6 NSO.sub.2 (CH.sub.2).sub.p -- or R.sub.7 SO.sub.2 NH(CH.sub.2).sub.p --, (where R.sub.5 and R.sub.6 each represents a hydrogen atom or a C.sub.1-3 alkyl group, R.sub.7 represents C.sub.1-3 alkyl and p is zero or one),R.sub.2 is hydrogen or C.sub.1-3 alkyl;R.sub.3 and R.sub.4 each represents hydrogen atom, C.sub.1-3 alkyl, or 2-propenyl;m is zero or an integer from 1 to 4; andn is an integer from 2 to 5; and physiologically acceptable salts and solvates (e.g. hydrates) thereof.The compounds have potent and selective vasoconstrictor activity and are indicated as useful for the treatment of migraine. They may be formulated as pharmaceutical compositions with pharmaceutically acceptable carriers of excipients for administration by any convenient route.Various methods for the preparation of the compounds (I) are disclosed.
    • 公开了式(I)的吲哚:其中R1表示R5R6NCOCH2-,R5CONH(CH2)p-,R5R6NSO2(CH2)p-或R7SO2NH(CH2)p-,(其中R5和R6各自表示 氢原子或C 1-3烷基,R 7表示C 1-3烷基,p为0或1),R 2为氢或C 1-3烷基; R3和R4各自表示氢原子,C1-3烷基或2-丙烯基; m为0或1至4的整数; n为2〜5的整数。 和其生理上可接受的盐和溶剂合物(例如水合物)。 这些化合物具有有效和选择性的血管收缩剂活性,并被用于治疗偏头痛。 它们可以配制成具有药学上可接受的赋形剂载体的药物组合物,用于通过任何方便的途径给药。 公开了制备化合物(I)的各种方法。
    • 6. 发明授权
    • Indole derivatives
    • 吲哚衍生物
    • US5270333A
    • 1993-12-14
    • US745896
    • 1991-08-16
    • David E. BaysAlexander W. Oxford
    • David E. BaysAlexander W. Oxford
    • C07D209/14C07D209/16A61K31/40
    • C07D209/14C07D209/16
    • Compounds are disclosed of general formula: ##STR1## wherein R.sup.1 is H, C.sub.1-6 alkyl or C.sub.3-6 alkenyl; R.sup.2 is H, C.sub.1-3 alkyl, C.sub.3-6 alkenyl, aryl, ar(C.sub.1-4)-alkylene, or C.sub.5-7 cycloalkyl;R.sup.3 is H or C.sub.1-3 alkyl;R.sup.4 and R.sup.5 each represents H, C.sub.1-3 alkyl or 2-propenyl, or R.sup.4 and R.sup.5 together form an aralkylidene group;R.sup.6 represents --CO.sub.2 R.sup.7, COR.sup.7, --COCO.sub.2 R.sup.7, or --CONHR.sup.7, whereR.sup.7 represents H, C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, C.sub.2-4 alkenyl, aryl or ar(C.sub.1-4)alkylene (with the provisos that (a) R.sup.7 does not represent H or benzyl when R.sup.6 is --CO.sub.2 R.sup.7 and (b) R.sup.7 does not represent alkenyl when R.sup.6 is --CONHR.sup.7); and Alk represents an alkylene chain containing two or three carbon atoms which may be unsubstituted or substituted by not more than two C.sub.1-3 alkyl group, and physiologically acceptable salts and solvates (e.g. hydrates) thereof.The compounds have potent and selective vasoconstrictor activity and are indicated as useful for the treatment of migraine. The compounds may be formulated as pharmaceutical compositions with physiologically acceptable carriers or excipients for administration by any convenient route. Various methods for the preparation of the compounds (I) are disclosed.
    • 公开了以下通式的化合物:其中R 1是H,C 1-6烷基或C 3-6烯基; R 2是H,C 1-3烷基,C 3-6烯基,芳基,芳(C 1-4) - 亚烷基或C 5-7环烷​​基; R3是H或C1-3烷基; R4和R5各自表示H,C1-3烷基或2-丙烯基,或R4和R5一起形成亚烷基; R 6表示-CO 2 R 7,COR 7,-COCO 2 R 7或-CONHR 7,其中R 7表示H,C 1-4烷基,C 3-7环烷基,C 2-4烯基,芳基或芳(C 1-4)亚烷基(条件是(a )当R 6为-CO 2 R 7时,R 7不表示H或苄基,(b)当R 6为-CONHR 7时,R 7不表示烯基); 并且Alk表示可以是未被取代的或被不多于两个C 1-3烷基取代的含有两个或三个碳原子的亚烷基链,以及其生理上可接受的盐和溶剂合物(例如水合物)。 这些化合物具有有效和选择性的血管收缩剂活性,并被用于治疗偏头痛。 这些化合物可以配制成具有生理上可接受的载体或赋形剂的药物组合物,用于通过任何方便的途径给药。 公开了制备化合物(I)的各种方法。
    • 7. 发明授权
    • 5-substituted 3-aminoalkyl indoles useful in treatment of migraine
    • 用于治疗偏头痛的5-取代的3-氨基烷基吲哚
    • US4672067A
    • 1987-06-09
    • US625648
    • 1984-06-28
    • Ian H. CoatesKeith MillsColin F. WebbMichael D. DowleDavid E. Bays
    • Ian H. CoatesKeith MillsColin F. WebbMichael D. DowleDavid E. Bays
    • C07D209/14A61K31/40A61K31/403A61K31/4035A61K31/404A61P9/00A61P25/04C07D209/16C07D209/48C07D471/04
    • C07D209/16
    • Compounds are disclosed of formula (I) ##STR1## wherein R.sub.1 represents CHO, COR.sub.8, CO.sub.2 R.sub.8, CONR.sub.9 R.sub.10, CSNR.sub.9 R.sub.10 or SO.sub.2 NR.sub.9 R.sub.10, whereR.sub.8 represents alkyl, cycloalkyl, aryl or aralkyl,R.sub.9 represents hydrogen or alkyl, andR.sub.10 represents hydrogen or alkyl, cycloalkyl, aryl or aralkyl;R.sub.2, R.sub.3, R.sub.4, R.sub.6 and R.sub.7 each independently represents hydrogen or C.sub.1-3 alkyl;R.sub.5 represents hydrogen, or alkyl, cycloalkyl, alkenyl or aralkyl, orR.sub.4 and R.sub.5 together form an aralkylidene group or R.sub.4 and R.sub.5 together with the attached nitrogen atom form a saturated monocyclic 5- to 7-membered ring; andAlk represents C.sub.2-3 alkylene chain optionally substituted by not more than two C.sub.1-3 alkyl groups;and physiologically acceptable salts and solvates thereof. The compounds are potentially useful for the treatment of migraine and may be formulated as pharmaceutical compositions in conventional manner using pharmaceutically acceptable carriers or excipients. The compounds may be prepared by, for example, reaction of an aminoalkyl indole with an acid of formula R.sub.1 OH or an acylating agent corresponding thereto or with an inorganic cyanate or an organic isocyanate or isothiocyanate in order to introduce the desired R.sub.1 group at the 5-position on the indole nucleus.
    • 公开了式(I)的化合物其中R 1表示CHO,COR8,CO 2 R 8,CONR 9 R 10,CSNR 9 R 10或SO 2 NR 9 R 10,其中R 8表示烷基,环烷基,芳基或芳烷基,R 9表示氢或烷基,R 10表示氢 或烷基,环烷基,芳基或芳烷基; R2,R3,R4,R6和R7各自独立地表示氢或C1-3烷基; R5表示氢或烷基,环烷基,烯基或芳烷基,或R4和R5一起形成芳烷叉基或R4和R5与连接的氮原子一起形成饱和的单环5-至7-元环; 并且Alk表示任选被不多于两个C 1-3烷基取代的C 2-3亚烷基链; 及其生理上可接受的盐和溶剂合物。 这些化合物潜在地可用于治疗偏头痛,并且可以使用药学上可接受的载体或赋形剂以常规方式配制成药物组合物。 化合物可以通过例如氨基烷基吲哚与式R1OH的酸或对应于其的酰化剂或与无机氰酸酯或有机异氰酸酯或异硫氰酸酯反应制备,以便在5- 在吲哚核上的位置。
    • 8. 发明授权
    • 3 amino alkyl indoles for use in treating migraine
    • 3氨基烷基吲哚,用于治疗偏头痛
    • US4636521A
    • 1987-01-13
    • US626383
    • 1984-06-29
    • Ian H. CoatesKeith MillsColin F. WebbMichael D. DowleDavid E. Bays
    • Ian H. CoatesKeith MillsColin F. WebbMichael D. DowleDavid E. Bays
    • C07D209/14A61K31/40A61K31/403A61K31/4035A61K31/404A61P9/00A61P25/04C07D209/16C07D209/48C07D471/04
    • C07D209/16
    • Compounds are disclosed of general formula (I) ##STR1## wherein R.sub.1 represents an alkyl, cycloalkyl, aryl or aralkyl group;R.sub.2, R.sub.3, R.sub.4, R.sub.6 and R.sub.7, which may be the same or different, each represents a hydrogen atom or a C.sub.1-3 alkyl group;R.sub.5 represents a hydrogen atom or an alkyl, cycloalkyl, alkenyl or an aralkyl group; or R.sub.4 and R.sub.5 together form an aralkylidene group or R.sub.4 and R.sub.5 together with the nitrogen atom to which they are attached form a saturated monocyclic 5- to 7-membered ring; Alk represents an alkylene chain containing two or three carbon atoms which may be unsubstituted or substituted by not more than two C.sub.1-3 alkyl groups; and physiologically acceptable salts, solvates and bioprecursors thereof. The compounds are described as potentially useful for the treatment of migraine and may be formulated as pharmaceutical compositions in conventional manner using one or more pharmaceutically acceptable carriers or excipients. Various processes for the preparation of the compounds are disclosed including, for example, a process involving reaction of an aminoalkyl indole with a sulphonylating agent in order to introduce the --SO.sub.2 -- group at the 5-position on the indole nucleus.
    • 公开了通式(I)的化合物其中R 1表示烷基,环烷基,芳基或芳烷基; R 2,R 3,R 4,R 6和R 7可以相同或不同,各自表示氢原子或C 1-3烷基; R5表示氢原子或烷基,环烷基,烯基或芳烷基; 或R 4和R 5一起形成亚烷基或R 4和R 5与它们所连接的氮原子一起形成饱和的单环5-至7-元环; Alk表示含有两个或三个碳原子的亚烷基链,其可以是未取代的或被不多于两个C 1-3烷基取代; 和其生理上可接受的盐,溶剂化物和生物前体。 这些化合物被描述为潜在地可用于治疗偏头痛,并且可以使用一种或多种药学上可接受的载体或赋形剂以常规方式配制成药物组合物。 公开了制备化合物的各种方法,包括例如涉及氨基烷基吲哚与磺酰化剂反应的方法,以便在吲哚核上的5-位引入-SO 2 - 基团。
    • 10. 发明授权
    • 5-Aminosulphoryl substituted indole derivatives
    • 5-氨基磺酰基取代的吲哚衍生物
    • US4876267A
    • 1989-10-24
    • US66498
    • 1987-06-26
    • Darko ButinaMichael D. DowleDavid E. BaysColin F. Webb
    • Darko ButinaMichael D. DowleDavid E. BaysColin F. Webb
    • A61K31/40A61K31/403A61K31/404A61P25/04A61P25/06C07D209/16
    • C07D209/16
    • Indole derivatives are disclosed of the formula (I): ##STR1## wherein R.sub.1 represents H, or C.sub.1-6 alkyl or C.sub.3-6 Alkenyl;R.sub.2 represents a H, C.sub.1-3 alkyl, C.sub.3-6 alkenyl or C.sub.5-7 cycloalkyl, or a phenyl or phen(C.sub.1-4)alkyl group in which the phenyl ring is optionally substituted by halogen or C.sub.1-3 alkyl, C.sub.1-3 alkoxy or hydroxyl, or by a group NR.sup.a R.sup.b, or CONR.sup.a R.sup.b, wherein R.sup.a and R.sup.b each independently represents H or C.sub.1-3 alkyl;R.sub.3 and R.sub.4, each independently represents H or C.sub.1-3 alkyl or 2-propenyl;and physiologically acceptable salts and solvates (e.g. hydrates) thereof.The compounds have potent and selective vasoconstrictor activity and are indicated as useful for the treatment of migraine. The compounds may be formulated as pharmaceutical compositions with pharmaceutically acceptable carriers or excipients for administration by any suitable means. Various methods for the preparation of the compounds are disclosed.
    • 公开了式(I)的吲哚衍生物:其中R 1表示H或C 1-6烷基或C 3-6烯基的(I) R 2表示H,C 1-3烷基,C 3-6烯基或C 5-7环烷​​基,或苯基或苯基(C 1-4)烷基,其中苯环任选被卤素或C 1-3烷基取代,C1- 3烷氧基或羟基,或NRaRb或CONRaRb基团,其中Ra和Rb各自独立地表示H或C1-3烷基; R 3和R 4各自独立地表示H或C 1-3烷基或2-丙烯基; 和其生理上可接受的盐和溶剂合物(例如水合物)。 这些化合物具有有效和选择性的血管收缩剂活性,并被用于治疗偏头痛。 这些化合物可以配制成具有药学上可接受的载体或赋形剂的药物组合物,用于通过任何合适的方式给药。 公开了制备化合物的各种方法。